Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bonus BioGroupXTAE:BONS -0.38%22 Market Cap is ₪309.50 Mil as of Aug. 01, 2026. GuruFocus rates XTAE:BONS with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 1,422 Biotechnology companies, Bonus BioGroup ranks worse than 51.27% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Bonus BioGroup's share price for the quarter that ended in Dec. 2025 was ₪0.251. Bonus BioGroup's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 1,167.93 Mil. Therefore, Bonus BioGroup's market cap for the quarter that ended in Dec. 2025 was ₪293.15 Mil.
Bonus BioGroup's quarterly market cap
increased
from Dec. 2024 (₪138.98 Mil) to Jun. 2025 (₪237.09 Mil) and
increased
from Jun. 2025 (₪237.09 Mil) to Dec. 2025 (₪293.15 Mil).
Bonus BioGroup's annual market cap
declined
from Dec. 2023 (₪195.04 Mil) to Dec. 2024 (₪138.98 Mil) but then
increased
from Dec. 2024 (₪138.98 Mil) to Dec. 2025 (₪293.15 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Bonus BioGroup's Enterprise Value for Today is ₪318.17 Mil.
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Bonus BioGroup Market Cap Related Terms
Bonus BioGroup Market Cap Historical Data
* Premium members only.
The historical data trend for Bonus BioGroup's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTAE:BONS vs VRTX, REGN, RVMD: Market Cap Comparison
For the Biotechnology subindustry, Bonus BioGroup's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bonus BioGroup Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bonus BioGroup's Market Cap distribution charts can be found below:
* The bar in red indicates where Bonus BioGroup's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Bonus BioGroup's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bonus BioGroup (XTAE:BONS) has a Market Cap of ₪309.50 Mil as of Aug. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Bonus BioGroup and its competitors. According to the industry distribution chart, Bonus BioGroup ranks #729 out of 1422 companies in the Biotechnology industry, placing it in the top 51.3%.
Is Bonus BioGroup's Market Cap too high?
Bonus BioGroup's current Market Cap is ₪309.50 Mil. Based on the distribution chart, Bonus BioGroup ranks #729 out of 1422 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Bonus BioGroup has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Bonus BioGroup's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bonus BioGroup ranks #729 out of 1422 companies for Market Cap. This places Bonus BioGroup in the lower half of its industry. The industry median Market Cap is 109.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 109.62, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Bonus BioGroup and its competitors. For the Biotechnology industry, the median Market Cap is 109.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bonus BioGroup's current Market Cap is ₪309.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bonus BioGroup stock overvalued right now?
Bonus BioGroup (XTAE:BONS) has a current Market Cap of ₪309.50 Mil. The current Market Cap is ₪309.50 Mil. Bonus BioGroup's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Bonus BioGroup (XTAE:BONS), the current Market Cap is ₪309.50 Mil as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bonus BioGroup Ltd is an clinical-stage biotechnology company developing next-generation therapies for a variety of indications in the regenerative medicine field. Its products products, BonoFill and MesenCure.
22GF Score
Get the complete analysis for XTAE:BONS
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:BONS has been successfully added to your 
